Prévisions

Acheter	2
Conserver	1
Vendre	0

Actualités Accéder au fil d'actualités

SINTX reports strong revenue growth in Q2 2026, stock falls after hours

SINTX recorded a 199% revenue increase in the second quarter of 2026 to $452,000 and improved its gross margin to 61.5%, while net loss widened to $2.7 million. The company reported initial commercial revenues for the SINAPTIC-Wedge system and orders from contract manufacturing customers of about $3.2 million. The stock finished the regular session slightly higher but declined after hours as investors weighed continued losses, high cash burn (cash $3.6 million) and doubts about the company’s ability to continue as a going concern. Management guidance sees revenue of $0.9–1.1 million for Q3 2026 and $1.0–1.3 million for Q4, and the company emphasized additional financing needs and ongoing execution risks. » Plus sur de.investing.com
SINTX signs supply agreement with EVONIK for SiN/PEEK composite for AI-assisted 3D printing manufacturing

SINTX Technologies has signed a supply agreement with Evonik for the industrial production of its patented silicon nitride‑PEEK (SiN/PEEK) composite for AI‑assisted additive manufacturing of patient‑specific implants. Evonik will produce the scalable composite filament to SINTX specifications, enabling SINTX to begin immediate manufacture of 3D‑printed vertebral body replacement implants and other indications. SINTX highlights the material’s antipathogenic surface properties, osteogenic potential and improved imaging, and intends to use it to support regulatory approvals and humanitarian applications. » Plus sur finanzen.net
SINTX Technologies closes private-label deal for OsseoSculpt and plans market launch

SINTX Technologies has signed a private-label agreement to supply the biologic OsseoSculpt, intended to complement the FDA‑cleared SINAPTIC Foot & Ankle Osteotomy Wedge System. The company reports initial commercial revenue from OsseoSculpt in Q3 2025 and plans a limited rollout at early‑adopter sites with a broader US launch in Q1 2026. In parallel, SINTX received 510(k) clearance for the SINAPTIC wedge system, a Notice of Allowance for an anti‑pathogenic silicon nitride technology, and raised about $3.8 million through option exercises, but remains under profitability pressure with negative EBITDA and sharply declining revenues. » Plus sur de.investing.com

Dividendes historiques Dividendes

Tous les indicateurs de dividendes Tous les indicateurs

En 2023, SINTX Technologies Inc a déjà versé 4,56€ de dividendes. Le dernier versement a eu lieu en juin 2023.

Données financières de l'entreprise

Au dernier trimestre, SINTX Technologies Inc a réalisé un chiffre d'affaires de 396,05k€ et un bénéfice net de −2,37 Mio€

(EUR)	juin 2026	YoY
Chiffre d'affaires	+396,05k	366,81%
Bénéfice brut	+243,59k	4.685,10%
Bénéfice net	−2,37 Mio	20,56%
EBITDA	−2,31 Mio	26,32%

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	+8,36 Mio€
Nombre d'actions	6,36 Mio
Plus haut/bas sur 52 semaines	+5,82€ - +1,20€
Dividendes	Non
Bêta	0,64
Ratio P/E	−0,28
Ratio PEG	0,00
Ratio P/B	+1,54
Ratio P/S	+7,04

Profil de l'entreprise

Sintx Technologies, Inc. ist ein Unternehmen für hochentwickelte Materialien, das sich mit der Erforschung, Entwicklung und Vermarktung von medizinischen Geräten beschäftigt, die mit Siliziumnitrid für biomedizinische, industrielle und antipathogene Anwendungen hauptsächlich in den Vereinigten Staaten hergestellt werden. Das Unternehmen bietet festes und poröses Siliziumnitrid, Siliziumnitrit-Pulver und Siliziumnitrid-Beschichtungsprodukte sowie Siliziumnitrid-Verbundwerkstoffe und Polyetherketonketon an. Das Unternehmen war früher unter dem Namen Amedica Corporation bekannt. Sintx Technologies, Inc. wurde 1996 gegründet und hat seinen Hauptsitz in Salt Lake City, Utah.

Nom	SINTX Technologies Inc
PDG	Eric K. Olson
Siège social	Salt Lake City, ut États-Unis
Site web	sintx.com
Secteur	Matériaux
Industrie	Produits chimiques
Introduction en bourse	13/02/2014
Employés	32